Compare Elder Pharma with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs JUBILANT LIFE SCIENCES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA JUBILANT LIFE SCIENCES ELDER PHARMA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x -0.2 15.2 - View Chart
P/BV x 0.1 1.8 5.7% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 ELDER PHARMA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
JUBILANT LIFE SCIENCES
Mar-19
ELDER PHARMA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs380898 42.3%   
Low Rs188618 30.4%   
Sales per share (Unadj.) Rs491.2572.0 85.9%  
Earnings per share (Unadj.) Rs-3.236.2 -8.8%  
Cash flow per share (Unadj.) Rs14.459.5 24.2%  
Dividends per share (Unadj.) Rs04.50 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs376.5301.9 124.7%  
Shares outstanding (eoy) m20.54159.28 12.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.61.3 43.6%   
Avg P/E ratio x-89.320.9 -426.7%  
P/CF ratio (eoy) x19.712.7 154.8%  
Price / Book Value ratio x0.82.5 30.1%  
Dividend payout %012.4 0.0%   
Avg Mkt Cap Rs m5,833120,694 4.8%   
No. of employees `000NA2.4 0.0%   
Total wages/salary Rs m2,17919,260 11.3%   
Avg. sales/employee Rs ThNM38,120.6-  
Avg. wages/employee Rs ThNM8,058.4-  
Avg. net profit/employee Rs ThNM2,414.3-  
INCOME DATA
Net Sales Rs m10,08991,108 11.1%  
Other income Rs m257357 71.8%   
Total revenues Rs m10,34691,466 11.3%   
Gross profit Rs m-79217,390 -4.6%  
Depreciation Rs m3613,709 9.7%   
Interest Rs m2,7562,198 125.4%   
Profit before tax Rs m-3,65311,840 -30.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,713-2,802 -132.5%   
Tax Rs m1253,268 3.8%   
Profit after tax Rs m-655,770 -1.1%  
Gross profit margin %-7.819.1 -41.1%  
Effective tax rate %-3.427.6 -12.4%   
Net profit margin %-0.66.3 -10.2%  
BALANCE SHEET DATA
Current assets Rs m9,24045,848 20.2%   
Current liabilities Rs m9,99820,897 47.8%   
Net working cap to sales %-7.527.4 -27.4%  
Current ratio x0.92.2 42.1%  
Inventory Days Days4657 81.5%  
Debtors Days Days6051 117.7%  
Net fixed assets Rs m10,12465,498 15.5%   
Share capital Rs m206159 129.1%   
"Free" reserves Rs m5,58247,930 11.6%   
Net worth Rs m7,73448,089 16.1%   
Long term debt Rs m4,88942,429 11.5%   
Total assets Rs m22,882114,685 20.0%  
Interest coverage x-0.36.4 -5.1%   
Debt to equity ratio x0.60.9 71.7%  
Sales to assets ratio x0.40.8 55.5%   
Return on assets %11.86.9 169.3%  
Return on equity %-0.812.0 -7.0%  
Return on capital %22.312.4 179.7%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m30712,422 2.5%   
Fx outflow Rs m12517,227 0.7%   
Net fx Rs m181-4,805 -3.8%   
CASH FLOW
From Operations Rs m11,75411,215 104.8%  
From Investments Rs m-561-10,118 5.5%  
From Financial Activity Rs m-6,7626,574 -102.9%  
Net Cashflow Rs m4,4327,612 58.2%  

Share Holding

Indian Promoters % 39.6 45.6 86.8%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 7.5 8.7 86.2%  
FIIs % 16.8 21.2 79.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 21.1 171.1%  
Shareholders   16,479 23,815 69.2%  
Pledged promoter(s) holding % 77.6 15.9 489.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  UNICHEM LAB  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare ELDER PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY19); Net Profit Up 25.7% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 25.7% YoY). Sales on the other hand came in at Rs 24 bn (up 15.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS